About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lupus Clinical Trials | 1,269 Studies Recruiting

Clinical TrialsLupus

Lupus Clinical Trials

Browse 1,269 clinical trials for lupus. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 101-120 of 1,269 trials

UnknownRegulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic TreatmentsB cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies.NCT01642706·Montpellier CompletedCCCR Lupus Patient Navigator ProgramTo address the health disparities in SLE outcomes for minorities, targeted intervention will be used to address the common barriers to care among patients; a comprehensive patient…NCT04461158·Charleston, South Carolina RecruitingBAFF CAR-T Cells (LMY-920) for Systemic Lupus ErythematosusThis phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus…NCT06340750·Columbus, Ohio CompletedImproving the Assessment of SLE Disease ActivityPhysicians' assessment of disease activity in SLE is fundamental but challenging.NCT03144063·Toronto, Ontario

Related Searches

sletrials systemic lupustrials

Data from ClinicalTrials.govTerms

RecruitingGonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by QuestionnairesBackground: Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. People with SLE are often treated with cyclophosphamide (CYC).NCT05567198·Bethesda, Maryland

CompletedPilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)This is an open label, pilot, observational, prospective study of the safety of inactivated influenza vaccine (IIV) in children with systemic lupus erythematosus (SLE) to be…NCT02006784·Dallas, Texas

CompletedFitness Integrative Training for Pediatric Rheumatology DisordersThis study evaluates the feasibility of the Fitness Integrative Training program for Teens (FIT Teens 2), a combined cognitive behavioral therapy and neuromuscular exercise…NCT06556992·Cincinnati, Ohio

WithdrawnThe Effect of Milnacipran on Fatigue and Quality of Life in Lupus PatientsSystemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease impacting the physical, social, psychological health and quality of life of patients.NCT01359826·Loma Linda, California

CompletedHighly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus ErythematosusIdentification of biological markers able to better stratify cardiovascular risks in systemic lupus erythematosus patients is needed.NCT04580108·Paris

Not yet recruitingFibroblast Growth Factor 21 in Systemic Lupus ErythematosusSystemic lupus erythematosus (SLE) is a chronic disorder characterized by profound immune and metabolic disturbances.NCT06842810

RecruitingUniversal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus ErythematosusThis investigator-initiated trial aims to evaluate the safety and efficacy of universal anti-CD70 CAR-T (CHT101) in patients with relapsed refractory systemic lupus erythematosus.NCT06946485·Nanjing, Jiangsu

Active not recruitingProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusSystemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems.NCT05843643·Chandler, Arizona and 368 others

CompletedPhenomics in Autoimmune and Inflammatory DiseasesThe family of inflammatory/autoimmune systemic diseases (IAD) form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of…NCT02466217·Paris and 1 other

UnknownScrutinizing the Heterogeneity of SLE: Defining PhenotypesSLE disease course is characterized by unpredictable relapses and remissions in the majority of patients.NCT03348774·Toronto, Ontario

CompletedDuke Autoimmunity in Pregnancy RegistryIt is difficult to predict how a women with an autoimmune disease will do during pregnancy. Some women will improve, others will worsen.NCT00513591·Durham, North Carolina

WithdrawnAllogeneic Stem Cell Transplantation in Systemic Lupus ErythematosusThis trial is designed to evaluate the safety of treating systemic lupus erythematosus participants with cyclophosphamide and CAMPATH-1H followed by allogeneic stem cell…NCT00278590·Chicago, Illinois

TerminatedA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus ErythematosusThis is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months…NCT00381810·Paradise Valley, Arizona and 10 others

CompletedA Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy ParticipantsThe primary objective of this study is to perform mass balance following a single oral dose of \[14C\]CCX168 in healthy adult male participants.NCT06004960·Madison, Wisconsin

RecruitingStudy of YK012 in Moderate to Severe Systemic Lupus ErythematosusThe goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with…NCT07010835·Beijing, Beijing Municipality

Not yet recruitingRD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune DiseasesThis is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA…NCT07674147·Nanjing, Jiangsu and 1 other

PreviousPage 6 of 64Next